Cmab has been used for R/M HNSCC regardless of EGFR expression, based on a sub-analysis of the EXTREME study in which EGFR copy number was reported to be not predictive of Cmab efficacy (41). Here, EGFR is linked to head and neck squamous cell carcinoma.